Vestcor Inc. significantly increased its stake in HCA Healthcare in the fourth quarter, now holding 26,268 shares valued at approximately $12.3 million. Despite recent target price cuts by some analysts, Wall Street generally maintains a "Moderate Buy" rating for HCA, with an average target price of $506.14. HCA Healthcare continues to demonstrate strong operational performance, reporting $19.1 billion in first-quarter revenue and expanding its network through strategic acquisitions.

Vestcor Inc significantly increased its stake in Monster Beverage Corporation (NASDAQ:MNST) by 30.3% in the fourth quarter, holding shares now valued at $13.29 million. This comes as Monster Beverage reported strong quarterly results, beating EPS and revenue expectations, and authorized a $500 million share repurchase plan. Despite recent insider selling, analysts maintain a "Moderate Buy" consensus for the stock with an average target price of $89.05.

HIVE Digital Technologies CFO Darcy Daubaras discussed the company's record fiscal year-end results driven by Bitcoin mining expansion in Paraguay and an accelerated AI infrastructure strategy. HIVE achieved a 104% increase in Bitcoin production and nearly $300 million in revenue, which underpins its investment in AI data centers. The company is projecting significant growth in high-performance computing, aiming for $200 million in annual run-rate revenue by year-end and $600 million long-term through strategic partnerships and data center developments.

This article lists various Exchange Traded Funds (ETFs) that hold HCA Healthcare Inc (HCA) stocks, providing detailed financial information for each. The data includes market value, weight of HCA in the ETF, issuer, management style, focus, expense ratio, assets under management (AUM), current price, change percentage, relative volume, and 3-year NAV total return. The ETFs cover a range of investment strategies from broad market and large-cap passive funds to specific sector and ESG-focused active funds.

Pfizer Inc. presented detailed results from Phase 2b studies for berobenatide (PF’3944), an investigational monthly GLP-1 receptor agonist peptide, highlighting its potential for competitive weight loss and favorable tolerability. The data support a planned Phase 3 program targeting chronic weight management and obesity-related comorbidities, with 10 studies for berobenatide in 2026. The findings suggest berobenatide could be the first approved monthly GLP-1 RA peptide, offering convenience and scalability for patients.

New data from Abbott reveals a significant rise in diabetic ketoacidosis (DKA) hospitalizations across all age groups, with nearly 60% of pediatric diabetes-related hospitalizations now driven by DKA. The company highlights that DKA is often misdiagnosed early due to symptoms mimicking common illnesses and notes a lack of routine ketone monitoring. Abbott has developed dual glucose-ketone sensors, Libre Duo and Libre Duo 10 Day, which have received CE Mark and are pending FDA clearance, aiming to provide earlier detection of rising ketone levels and prevent DKA.

This article lists various ETFs that hold Lamb Weston Holdings, Inc. stocks, providing details such as market value, weight, issuer, management style, expense ratio, AUM, price, change, and 3-year NAV total return. The ETFs cover a range of investment strategies, including small-cap, total market, mid-cap, value, and consumer staples, offering diverse options for investors interested in companies like Lamb Weston.

This article lists various Exchange Traded Funds (ETFs) that hold shares in Liberty Media Corporation Series C Liberty Formula One (LM0F), presented as a resource for investors. The table provides detailed financial metrics for each ETF, including market value, weight of LM0F in the fund, issuer, management style, focus, expense ratio, assets under management (AUM), price, and 3-year NAV total return. The ETFs cover a range of strategies from total market and small-cap to mid-cap and communication services, with both passive and active management styles.

The Pumpkin Spice Latte from Starbucks has become a significant US fall tradition, blending espresso, milk, and warm spices into a seasonal drink that defines the brand’s autumn menu and inspires many imitations. This article explores how the PSL signals the start of fall for US consumers and drives recurring revenue for coffee retailers by leveraging seasonal anticipation. It also discusses the beverage's market impact, customization options, and the broader expansion of pumpkin spice products into home and international markets.

Starbucks is bringing back its iconic Unicorn Frappuccino nationwide this summer for a limited time. First introduced in 2017, the colorful drink with mango syrup, pink powder, and sweet/sour swirls became an Instagram sensation. While it made a brief appearance at Coachella earlier this year, this will be its first widespread return, expected to launch in July or August to "close out the summer."